Aug. 07 Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course Alphavalue
Aug. 07 Genmab A/S, H1 2026 Earnings Call, Aug 06, 2026
Aug. 07 UBS raises Genmab price target to 2,700 Danish kroner (2,600), reiterates buy FW
Aug. 07 Genmab soars after raising its guidance Zonebourse
Aug. 07 Analysts upbeat on Genmab after strong Q2 FW
Aug. 07 Goldman Sachs raises Genmab target price to 2,400 Danish kroner (2,350), reiterates buy - BN FW
Aug. 07 TD Cowen raises Genmab price target to 2,892 Danish kroner (2,851), reiterates buy FW
Aug. 07 Jyske Bank raises Genmab target price to 2 350 Danish kroner (2 300), reiterates buy - BN FW
Aug. 07 Nordea raises its target price for Genmab to 2,083 Danish kroner (2,015), reiterates buy FW
Aug. 06 Genmab A/S Revises Earnings Guidance for the Year 2026 CI
Aug. 06 Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 06 Genmab Lifts FY26 Earnings Guidance MT
Aug. 06 Genmab boosts operating profit more than expected, raises guidance (update 2) FW
Aug. 06 Genmab A/S : Interim Report for the First Half of 2026 PU
Aug. 06 Genmab boosted operating profit more than expected, raises forecasts (update) FW
Aug. 06 Genmab boosted operating profit more than expected FW
Aug. 06 Genmab Announces Financial Results for the First Half of 2026 GL
Jul. 23 Stocks to Watch : Intel, Deckers, Edwards Lifesciences, Genmab DJ
Jul. 23 Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) GL
Jul. 23 Genmab A/S and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma CI
Jul. 22 TD Cowen Upgrades Genmab to Buy Rating, Boosts PT MT
Jul. 22 TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32 MT
Jul. 22 TD Cowen upgrades Genmab to buy (hold) - BN FW
Jul. 21 Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN FW
Jul. 15 Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales MT
No results match your criteria